Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Patent metadata

Field	Value
Publication number	US-12435149-B2
Application number	US-201816623750-A
Country	US
Kind code	B2
Filing date	Jun 20, 2018
Priority date	Jun 20, 2017
Publication date	Oct 7, 2025
Grant date	Oct 7, 2025

Abstract

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

First claim

What is claimed is:

1. An isolated antigen binding protein that specifically binds to a human gastric inhibitory peptide receptor (GIPR) polypeptide, wherein said antigen binding protein is an antibody or a fragment thereof, wherein the fragment is a Fab fragment, a Fab′ fragment, or a F(ab′)2 fragment, and wherein said antibody is a GIPR antagonist and comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein each CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3, respectively, comprises SEQ ID NO: 1290, SEQ ID NO: 1291, SEQ ID NO: 1292, SEQ ID NO: 1293, SEQ ID NO: 1294, and SEQ ID NO: 1295.

2. A method of treating a subject with a metabolic disorder, the method comprising administering to the subject a therapeutically effective amount of an antigen binding protein according to claim 1 .

3. The method of claim 2 , wherein said metabolic disorder is a disorder of glucose metabolism.

4. The method of claim 3 , wherein said glucose metabolism disorder comprises hyperglycemia and wherein said administering reduces plasma glucose in said subject.

5. The method of claim 3 , wherein said glucose metabolism disorder comprises hyperinsulinemia and wherein said administering reduces plasma insulin in said subject.

6. The method of claim 3 , wherein said glucose metabolism disorder comprises glucose intolerance and wherein said administering increases glucose tolerance in said subject.

7. The method of claim 3 , wherein said glucose metabolism disorder comprises insulin resistance and wherein said administering decreases insulin resistance in said subject.

8. The method of claim 3 , wherein said glucose metabolism disorder comprises diabetes mellitus.

9. The method of claim 3 , wherein said subject is obese.

10. The method of claim 9 , wherein said administering reduces body weight in said subject.

11. The method of claim 9 , wherein said administering reduces body weight gain in said subject.

12. The method of claim 9 , where said administering reduces fat mass in said subject.

13. The method of claim 9 , wherein said glucose metabolism disorder comprises insulin resistance and wherein said administering reduces insulin resistance in said subject.

14. The method of claim 9 , where said subject has increased liver steatosis, and wherein said administering reduces liver steatosis in said subject.

15. The method of claim 9 , where said subject has increased liver fat content, and wherein said administering reduces liver fat content in said subject.

16. The method of claim 2 , wherein said subject is a mammal.

17. The method of claim 2 , wherein said subject is human.

18. The method of claim 2 , wherein said administering is by parenteral injection.

19. The method of claim 2 , wherein said administering is by subcutaneous injection.

20. The isolated antigen binding protein of claim 1 , wherein said human GIPR has a sequence comprising a sequence selected from the group consisting of SEQ ID NO: 1201, SEQ ID NO: 1203, and SEQ ID NO: 1205.

21. The isolated antigen binding protein of claim 20 , wherein said antigen binding protein is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

22. The isolated antigen binding protein of claim 21 , wherein said antigen binding protein is a monoclonal antibody.

23. The isolated antigen binding protein of claim 21 , wherein said antigen binding protein is of the IgG1-, IgG2-IgG3- or IgG4-type.

24. The isolated antigen binding protein of claim 23 , wherein said antigen binding protein is of the IgG1- or the IgG2-type.

25. The isolated antigen binding protein of claim 21 , wherein said antigen binding protein is coupled to a labeling group.

26. The isolated antigen binding protein of claim 21 , wherein said antigen binding protein inhibits binding of GIP to the extracellular portion of human GIPR.

27. The isolated antigen binding protein of claim 21 , wherein said antigen binding protein is an antibody or a fragment thereof, and wherein said antibody or fragment thereof comprises a light chain variable region comprising SEQ ID NO: 1286 and a heavy chain variable region comprising SEQ ID NO: 1287.

28. The isolated antigen binding protein of claim 21 , wherein said antigen binding protein is an antibody, and wherein said antibody comprises a light chain comprising SEQ ID NO: 1288 and a heavy chain comprising SEQ ID NO: 1289.

29. A nucleic acid molecule encoding the antibody or fragment thereof according to claim 1 .

30. The nucleic acid molecule according to claim 29 , wherein said nucleic acid molecule is operably linked to a control sequence.

31. A vector comprising a nucleic acid molecule according to claim 30 .

32. A host cell comprising the vector according to claim 31 .

33. A method of making the antibody or fragment thereof according to claim 1 , comprising the step of preparing said antibody or fragment thereof from a host cell that secretes said antibody.

34. A pharmaceutical composition comprising at least one antibody or fragment thereof according to claim 1 , and pharmaceutically acceptable excipient.

35. A composition comprising a therapeutically effective amount of a GLP-1 receptor agonist and a therapeutically effective amount of a GIPR antagonist, wherein the GIPR antagonist is the antigen binding protein of claim 1 .

36. The composition of claim 35 , wherein the molar ratio of a GLP-1 receptor agonist to a GIPR antagonist is from 1:1 to 1:110, 1:1 to 1:100, 1:1 to 1:75, 1:1 to 1:50, 1:1 to 1:25, 1:1 to 1:10, 1:1 to 1:5, or 1:1.

37. The composition of claim 35 , wherein the molar ratio of a GIPR antagonist to a GLP-1 receptor agonist is from 1:1 to 1:110, 1:1 to 1:100, 1:1 to 1:75, 1:1 to 1:50, 1:1 to 1:25, 1:1 to 1:10, or 1:1 to 1:5.

38. The composition of claim 35 , wherein the GLP-1 receptor agonist is in combination with the GIPR antagonist at therapeutically effective molar ratios of between 1:1.5 to 1:150.

39. The composition of claim 38 , wherein the GLP-1 receptor agonist is in combination with the GIPR antagonist at therapeutically effective molar ratios of between 1:2 to 1:50.

40. The composition of claim 35 , wherein the GLP-1 receptor agonist and the GIPR antagonist are present in doses that are at least 1.1 to 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold lower than the doses of each compound alone required to treat a condition and/or disease.

41. The composition of claim 35 , wherein the GLP-1 receptor agonist is GLP-1(7-37) or a GLP-1(7-37) analog.

42. The composition of claim 41 , wherein the GLP-1 receptor agonist is selected from the group consisting of exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, and taspoglutide.

43. The composition of claim 35 , wherein the GLP-1 receptor agonist is selected from the group consisting of GLP-1(7-37) (SEQ ID NO: 1244); GLP-1(7-36)-NH 2 (SEQ ID NO: 1245); liraglutide; albiglutide; taspoglutide; dulaglutide, semaglutide, LY2428757; desamino-His 7 ,Arg 26 ,Lys 34 (N ε -(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37) (core peptide disc

Assignees

• Amgen Inc

Inventors

• Bates Darren L
• Shi Donghui
• Lloyd David J
• Bondarenko Pavel
• Michaels Mark L
• Hager Todd
• Min Xiaoshan
• Umeda Aiko
• Chen Irwin
• Wang Zhulun

Classifications

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/54

  F(ab')2 · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• A61K38/26

  Glucagons · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title